Here’s What Makes Argenx SE (ARGX) a Good Investment Option

Baron Funds, an asset management firm, published its “Baron Health Care Fund” second quarter 2022 investor letter – a copy of which can be downloaded here. In the quarter ended June 30, 2022, Baron Health Care Fund (the “Fund”) declined 10.00% (Institutional Shares), compared with the 7.43% decline for the Russell 3000 Health Care Index (the “Benchmark”) and the 16.10% decline for the S&P 500 Index. Since its inception (April 30, 2018), the Fund increased 15.00% on an annualized basis compared with the 11.96% gain for the Benchmark and the 10.91% gain for the S&P 500 Index. Go over the fund’s top 5 positions to have a glimpse of its finest picks for 2022.

In its Q2 2022 investor letter, Baron Health Care Fund mentioned argenx SE (NASDAQ:ARGX) and explained its insights for the company. Founded in 2008, argenx SE (NASDAQ:ARGX) is a Netherlands-based biotechnology company with a $20.7 billion market capitalization. argenx SE (NASDAQ:ARGX) delivered a 7.63% return since the beginning of the year, while its 12-month returns are up by 21.19%. The stock closed at $376.91 per share on August 12, 2022.

Here is what Baron Health Care Fund has to say about argenx SE (NASDAQ:ARGX) in its Q2 2022 investor letter:

“Argenx SE is a biotechnology company focused on autoimmune disorders. Shares increased given the strong launch of Vyvgart, a treatment for generalized myasthenia gravis, a chronic autoimmune disease that causes muscle weakness. Early sales tripled consensus expectations and global approvals are coming in earlier than guided. Data from Vyvgart’s trial to treat immune thrombocytopenia was positive as well. We expect the next two years to have many catalysts, and, assuming a well-received commercial launch, 2022 should be another year of solid performance.”

louis-reed-pwcKF7L4-no-unsplash

Our calculations show that argenx SE (NASDAQ:ARGX) fell short and didn’t make it on our list of the 30 Most Popular Stocks Among Hedge Funds. argenx SE (NASDAQ:ARGX) was in 31 hedge fund portfolios at the end of the second quarter of 2022, compared to 30 funds in the previous quarter. argenx SE (NASDAQ:ARGX) delivered a 20.94% return in the past 3 months.

In February 2022, we also shared another hedge fund’s views on argenx SE (NASDAQ:ARGX) in another article. You can find other investor letters from hedge funds and prominent investors on our hedge fund investor letters 2022 Q2 page.

Disclosure: None. This article is originally published at Insider Monkey.